Destiny Pharma PLC (AIM:DEST) chief scientific officer Bill Love spoke to Proactive as the company's XF-73 antibacterial drug begins a clinical study to prepare for a new drug application in the US.
He explains the importance of developing this and Destiny's other lead drug amid the rise in antimicrobial resistance, how they work compared to antibiotics, how they can be used to reduce hospital-acquired infections and the size of the potential market.
"We really do lead the world in this particular area with this type of approach," Love says, with potential peak annual sales above US$1bn for post-surgical infection product and the market to prevent C Difficile infection is seen growing to nearly US$3bn by 2025.